why choose us

First received: February 27, 2023

Clinical Trial: Evaluation of Butyrate and Palmitoylethanolamide in IBS Patients (B/P3_1)

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Irritable Bowel Syndrome With Diarrhea

Study Type: INTERVENTIONAL


Official Title: Evaluation of Butyrate and Palmitoylethanolamide Effects on Intestinal Permeability and Microbiota Gut Composition in Patients With Irritable Bowel Syndrome - A Double-blind, Placebo-controlled Crosso

Brief Summary: Evaluation of the effects of butyrate ( BitirBioma) and palmitoylethanolamide( PEA=PeaBioma) on intestinal permeability and gut microbiota composition in patients with irritable bowel syndrome.Study B/P 3_1 is an interventional study involving the use of food supplements on the market (BitirBioma Plus and PeaBioma Plus), single-center, double-blind, placebo-controlled, crossover, randomized, in n=50 patients with bowel syndrome irritable, diarrheal and mixed variant (IBS-D and IBS-M), lasting for one year.The…

Read more